Bruno Jorge Fagali is a well-known Brazilian attorney who specializes in Administrative Law, Regulatory Law, Urban Law, Anti-corruption Law, Advertising Law, Parliamentary Law, Ethics, and Compliance. Bruno is considered as a fast rising lawyer who hails from Brazil. Also, he is known for adding new dimensions to the nation’s legal system. Bruno Fagali has years of in-depth knowledge and experience in Administrative Law making himself an unparalleled reputation for himself. Apart from being an Administrative Law Specialist, his professional life is also focused on the area of Public Administration Control.
Career Background of Bruno Fagali
Since 2006, Bruno Fagali has involved himself in various law firms where he has practiced different legal disciplines. Currently, he serves as a Corporate Integrity Manager in Nova in the State of São Paulo, Brazil. He also practices independently through Fagali Advocacy where he serves as a founding partner of his agency/law Firm. In other words, Bruno Fagali is a specialist lawyer with a vast experience in both academic and professional law.
Bruno Fagali is in charge of the implementation and training of the Corporate Integrity Program and teams from Rio de Janeiro and São Paulo. Mr. Fgali has been responsible and in charge of the management of the Corporate Integrity for 24 months. Bruno Fagali is also an active coordinator and associate of an advertising agency and ethics committee known as the Brazilian Institute of Business Law and Ethics.
For more, take a peek at http://fagali.jusbrasil.com.br/.
Amicus Therapeutics is a young company which was created at the beginning of 2002. It is based in the city of Cranbury, New Jersey, and its industry is biopharmaceutics. The company currently has more than a hundred people in its workforce. The leader of the Amicus Therapeutics is Mr. John F. Crowley who is at the position of the chief executive officer (CEO). Mr. John F. Crowley has been the chief executive officer of Amicus Pharmaceuticals since the year of 2005. Five years later in 2010, Mr. John Crowly assumed the post of Chairman of the Board succeeding Mr. Donald Hayden, Jr.
Amicus Therapeutics has a focus on lysosomal storage disorders which is a collective term for a number of rare and orphan diseases. Amicus Therapeutics develops products through a system that vastly depends on the platform of CHART® – Chaperone-Advanced Replacement Therapy. This platform concentrates on the development of enzyme replacement therapies.
Over the years the company of Amicus Therapeutics has expanded through therapy development and acquisitions as well. The company indeed picked up the pace and was recognized a few years ago in 2014. It was noted for supposedly having one of broadest of portfolios in the industry regarding small molecule pharmacological chaperones. Amicus Therapeutics has been collaborating with some other companies such as Shire, JCR Pharmaceutical, GlaxoSmithKline, and more. Some of the partnerships lasted up to three years.
The acquisition of Amicus Therapeutics started up in 2013. That year was a winning one for Amicus Therapeutics as it acquired one of its competitors – Callidus Biopharma. That allowed Amicus Therapeutics to become a proprietor of the treatment for the Pompe Disease which is based on an enzyme replacement therapy (GoogleFinance). In September 2015, another acquisition followed. Amicus Therapeutics bought Scioderm for nearly a billion dollars as well as stock. That expanded Amicus Therapeutics and provided a clearer way ahead.
Amicus Therapeutics currently has a few medications on the market. The company mostly focuses on research. It expanded and set up another study site inSan Diego in 2008. The work was going smoothly up until the year, but after a while, the company was back on its feet and better than ever.
More here : https://www.glassdoor.com/Reviews/Amicus-Therapeutics-Reviews-E26068.htm
Alexandre Gama is a 59-year old Brazilian serving as the CEO and founder of Neogama. Neogma is among the top twenty publicity organizations in Brazil. Additionally, Mr. Alexandre is a global advertising authority and the first Brazil national to take part in Global Creative Board. Global Creative Board is a committee comprising six active leaders from globally recognized companies. It implies he is not limited to Neogama, but also plays crucial roles in the entire advertising sector.
Details Concerning Gama’s Profession
Alexandre attended Fundação Armando Alvares Penteado where he pursued a course in Advertising and propaganda. In 1982, his career path started shining when he enrolled as a writer at agency Standart. Again he joined DM9 in 1990 and assumed the role of a copywriter, duties he executed for four years. By that time he had already been recognized as the most awarded Brazilian writer. Gama got involved in several organizations before founding Neogama in 1999. He is an excellent authority who involves himself in campaigns defending communication industries’ rights.
Fundamentals Regarding Alexandre’s Neogama
Alexandre Gama launched Neogama in 1999. Within its first three years, Neogama was recognized as the fastest growing company in Brazil. Neogama also scooped two Golden Lions at Cannes in 2003, which was an indelible mark following that it was the first agency in Brazil to win such. The company has since registered tremendous improvement under Gama’s leadership. Advertising experts have, in several occasions, elected Alexandre Gama among prominent advertisers in Brazil. They do so in appreciation of Gama’s unparalleled expertise in the specialty.